ACRV vs MRNA · $65.1M cap vs rev $145.0M
Acrivon Therapeutics, Inc. Common Stock (ACRV) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
Acrivon Therapeutics, Inc. Common Stock (ACRV) is a biotechnology company listed on NASDAQ.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stéphane Bancel M.B.A..
ACRV does not have a complete income-statement cache yet.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
ACRV currently screens at market cap $65.1M. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the ACRV and MRNA stock pages for the full models.
Not investment advice.